louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05822622: Relationship Between Heart Failure With Preserved Ejection Fraction and Nonalcoholic Fatty Liver Disease.
Official title: Relationship Between Heart Failure With Preserved Ejection Fraction and Nonalcoholic Fatty Liver Disease.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Heart Failure With Preserved Ejection Fraction
Non Alcoholic Fatty Liver
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2023-04-21
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: all patients presented by heart failure with preserved ejection fraction and those with fatty liver disease

Brief summary: The aim of our study to determine the demography, relation between patients with heart failure with preserved ejection fraction and those with nonalcoholic fatty liver disease in Sohag university hospital.

Detailed description: type of the study cross sectional study to study the relationship between heart failure with preserved ejection fraction and nonalcoholic fatty liver disease.

Eligibility criteria: Inclusion Criteria: clinical diagnosis of heart failure with preserved ejection fraction.

clinical diagnosis of nonalcoholic fatty liver disease. -

Exclusion Criteria: rheumatic heart disease ,congenital heart disease , ischemic heart disease ,heart failure with reduced ejection fraction , hepatitis B virus , hepatitis C virus .

-

Primary outcomes:
measure: collection of results of echocardiography (those detect HFpEF) with abdominal ultrasound and transient elastography results (those detect NAFLD) and find relationship between the results.
timeFrame: up to 28 weeks.
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Asmaa elsayed khalifa
state: El Monshah
city: Sohag
country: Egypt
facility: Asmaa E khalifa
Study officials:
affiliation: Sohag University
name: Aml K Ahmed, A professor
role: STUDY_CHAIR
affiliation: Sohag University
name: Alshimaa L Hamed, lecturer
role: STUDY_CHAIR
References:
citation: Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017 Apr;3(1):7-11. doi: 10.15420/cfr.2016:25:2.
Clinical trial NCT04598022: Revealing Microbiome Association With (Plant-based) Diet in Freshman
Official title: Revealing Microbiome Association With (Plant-based) Diet in Freshman
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Healthy
Keywords: freshman
vegan
vegetarian
omnivore
microbiome
meal frequency
meal timing
freshman weight gain
metabolome
Lead sponsor: University of Kiel
Sponsor class: OTHER
First posted: 2020-10-22
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: healthy university / college freshmen studying in Kiel, Germany

Brief summary: Aim of the study is to evaluate the impact of a vegan vs. vegetarian dietary pattern compared to an omnivore diet on body weight, saliva and stool microbiome profiles, as well as saliva, urine and plasma metabolome profile changes in freshmen after the first year at university/college.


Eligibility criteria: Inclusion Criteria:

* freshman
* following a vegan / vegetarian / omnivore dietary pattern for at least 3 months
* own a smartphone (including internet access and camera)

Exclusion Criteria:

* regular use of medication (excluding oral contraceptiva)
* use of antibiotics in the last 6 weeks
* chronic disease, especially gut diseases
* following a vegan / vegetarian / omnivore dietary pattern for less then 3 months
* no clear assignment of vegan / vegetarian / omnivore dietary pattern
* electrical implants

Primary outcomes:
measure: change in body weight
timeFrame: one year
measure: change in fat mass
timeFrame: one year
Secondary outcomes:
measure: saliva metabolome
timeFrame: one year
measure: gut microbiome
timeFrame: one year
Other outcomes:
Locations:
city: Kiel
country: Germany
facility: Institute of Human Nutrition
Study officials:
affiliation: Institute of Human Nutrition, Kiel University
name: Anja Bosy-Westphal, PhD, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00380822: Double-Blind Study of Miglitol in Japanese With type2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Type 2 Diabetes Mellitus
Keywords: alpa-glucosidase inhibitor
Lead sponsor: Sanwa Kagaku Kenkyusho Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2006-09-27
Sex: ALL
Minimum age (years): 20
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To investigate the efficacy and safety of miglitol in Japanese patients with type 2 diabetes that is insufficiently controlled diet alone.


Eligibility criteria: Inclusion Criteria:

* Type2 diabetic patient on Dietary Therapy
* Criteria for postprandial plasma glucose and HbA1c are met

Exclusion Criteria:

* Type1 diabetes
* Patients treated with antidiabetic drugs or Insulin

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Aichi
country: Japan
city: Chiba
country: Japan
city: Fukuoka
country: Japan
city: Gunma
country: Japan
city: Hiroshima
country: Japan
city: Hyogo
country: Japan
city: Ibaragi
country: Japan
city: Ishikawa
country: Japan
city: Iwate
country: Japan
city: Kumamoto
country: Japan
city: Kyoto
country: Japan
city: Mie
country: Japan
city: Miyagi
country: Japan
city: Nagasaki
country: Japan
city: Niigata
country: Japan
city: Oita
country: Japan
city: Okayama
country: Japan
city: Osaka
country: Japan
city: Saga
country: Japan
city: Saitama
country: Japan
city: Shiga
country: Japan
city: Shimane
country: Japan
city: Shizuoka
country: Japan
city: Tokyo
country: Japan
city: Toyama
country: Japan
city: Yamagata
country: Japan
city: Yamaguchi
country: Japan
Study officials:
affiliation: Sanwa Kagaku Kenkyusho Co., Ltd.
name: Clinical study Group, Clinical Development Dept.
role: STUDY_DIRECTOR
References:
Clinical trial NCT02939222: Impact of Buccal Bone Thickness on Pathological Peri-implant Bone Loss: A 3-year Prospective Cohort Study
Official title: Impact of Buccal Bone Thickness on Pathological Peri-implant Bone Loss: A 3-year Prospective Cohort Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Periimplantitis
Oral Surgery
Lead sponsor: Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, Spain
Sponsor class: OTHER
First posted: 2016-10-19
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Implant placement may trigger bone trauma, which might result in 3-dimensional bone changes. While the process of peri-implant disease is not well understood, implant position within the bony structure might play a role. However, there is no data available on this regard.


Eligibility criteria: Inclusion Criteria:

* Patients between 18 and 80 years old
* Patients requiring oral rehabilitation through supported prosthesis
* Patients with partial edentulism
* No antibiotic in the last 2 months
* No smoking or smoking \<10 cigarettes a day

Exclusion Criteria:

* Systemic diseases uncontrolled
* Implants that because prosthetic characteristics can not be registered probing depth or attachment level appropriately
* Smoking\> 10 cigarettes a day
* Pregnant Patients
* Implants that can not be followed in CICOM
* Patients who do not return to regular maintenance therapy every 3-6meses
* Patients who are not controlled periodontal disease

Primary outcomes:
measure: Frequency of peri-implantitis
timeFrame: 3-years
Secondary outcomes:
Other outcomes:
Locations:
city: Badajoz
country: Spain
facility: Centro de Implantologia Cirugia Oral y Maxiofacial
Study officials:
References:
Clinical trial NCT01806922: Yoga Exercise for Improving Balance in Patients With Subacute &Ｃhronic Stroke
Official title: Yoga Exercise for Improving Balance in Patients With Subacute &Ｃhronic Stroke : A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression
Stroke
Keywords: Yoga
Stroke
Standing balance
Depression
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2013-03-07
Enrollment: 40
Sex: ALL
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hypothesis: This study investigated the hypothesis that subacute and chronic stroke patients who received a combination of yoga and traditional physiotherapy were getting more improvement in standing balance than traditional physiotherapy. And we also hypothesis yoga can improve post-stroke depression symtom.


Eligibility criteria: Inclusion Criteria:

1. The time of stroke onset is more than 91 days.
2. Able to stand for more than 1 minutes.
3. Between the ages of 30 and 80.

Exclusion Criteria:

1. Now receive others palliative therapy.
2. Significant psychotic disease.
3. Obvious language disorder.
4. Medical contraindication(clincans evaluate cannot included).

Primary outcomes:
measure: Berg Balance Scale
timeFrame: within 7 days after finish yoga therapy course
Secondary outcomes:
measure: Taiwanese Depression Questionnaire
timeFrame: within 7 days after finish yoga therapy course
Other outcomes:
Locations:
city: Hsin-Chu
country: Taiwan
facility: National Taiwan University Hospital Hsin-Chu Branch
Study officials:
affiliation: National Taiwan University Hospital Hsin-Chu Branch
name: Yen-Ting Lai
role: PRINCIPAL_INVESTIGATOR
References:
citation: 1.Tyson SF, Hanley M, Chillala J, Selley A, Tallis RC. Balance disability after stroke. Phys Ther. 2006;86:30. 2.Jorgensen L, Engstad T, Jacobsen BK. Higher incidence of falls in long-term stroke survivors than in population controls: Depressive symptoms predict falls after stroke. Stroke. 2002;33:542-547 3.Balance retraining after stroke using force platform biofeedback. Phys Ther. 1997 ; 77;553-58. 4.A yoga-based exercise program for people with chronic poststroke hemiparesis. Bastille JV, Gill-Body KM. Phys Ther. 2004 Jan;84(1):33-48. 5.Poststroke balance improves with yoga: a pilot study.Schmid AA, Van Puymbroeck M, Altenburger PA, Schalk NL, Dierks TA, Miller KK, Damush TM, Bravata DM, Williams LS. Stroke. 2012 Sep;43(9):2402-7. Epub 2012 Jul 26. 6.Chan W, Immink MA, Hillier S. Yoga and exercise for symptoms of depression and anxiety in people with poststroke disability: a randomized, controlled pilot trial. Altern Ther Health Med. 2012 May-Jun;18(3):34-43.
Clinical trial NCT03183622: A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-BI-101 Clinical Trial
Official title: A Follow-up Study to Evaluate the Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 1 Clinical Trial of ALLO-ASC-BI-101
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Burn
Keywords: Deep Second-Degree Burn Wound
Lead sponsor: Anterogen Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2017-06-12
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Subject is enrolled who are treated with ALLO-ASC-DFU sheet in phase 1 clinical trial of ALLO-ASC-BI-101

Brief summary: This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial(ALLO-ASC-BI-101) for 23 months.

Detailed description: This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial (ALLO-ASC-BI-101) for 23 months.

ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.

Eligibility criteria: Inclusion Criteria:

1. Subjects who are treated with ALLO-ASC-DFU sheet in phase 1 clinical trial of ALLO-ASC-BI-101.
2. A subject who is willing to follow the protocol and provide informed consent on screening, given that the information with respect to the clinical trial is provided.

Exclusion Criteria:

1. Subjects who are considered not suitable for the study by the principal investigator. (For example, Subjects requiring surgical procedure on target site)

Primary outcomes:
measure: Number of Participants with Adverse Events as a Measure of Safety and Tolerability
timeFrame: up to 24 months
Secondary outcomes:
measure: Vancouver Burn Scar Scale
timeFrame: Every time of visit for follow up to 24 months
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Hallym university Medical Center
Study officials:
affiliation: Hallym University Medical Center
name: Wook Chun, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04872322: Effect of Ropivacaine During Popliteal Nerve Block in Foot and Ankle Surgery
Official title: Randomized Study of the Effect of Initial Ropivacaine Dosage During Continuous Popliteal Nerve Blocks on Rebound Pain in Foot and Ankle Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Popliteal Nerve Block
Foot Surgery
Ankle Surgery
Lead sponsor: Rothman Institute Orthopaedics
Sponsor class: OTHER
First posted: 2021-05-04
Enrollment: 128
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: With the increasing rise of outpatient surgery in orthopaedic procedures, the management of immediate postoperative pain has been a major topic investigated, with the use of a peripheral nerve block in combination with general anesthesia being a commonly accepted method. Foot and ankle procedures, which offer the choice of several anesthetic techniques, have increasingly been performed with this method predominantly through the combination of general anesthesia with a single-injection popliteal nerve block to reduce the substantial acute postoperative pain that often requires large opioid intake within the post-anesthesia care unit (PACU). However, as a single-injection peripheral nerve block resolves off shortly following surgery, major postoperative pain, termed "rebound pain", can also arise, and has the potential to be even greater than that of patients who do not receive any peripheral nerve block with general anesthesia.

The purpose of this study is to evaluate the contribution of ropivacaine concentration (0.5% versus 0.25%) of the initial bolus in continuous popliteal nerve blocks toward the rebound pain phenomena, or the quantifiable difference in pain experienced during the initial time after block resolution, in foot and ankle surgeries.


Eligibility criteria: Inclusion Criteria:

* All patients undergoing foot and ankle surgeries under the care of Dr. Steven Raikin with continuous popliteal blocks at Riverview Surgical Center will be considered for enrollment.

Exclusion Criteria:

* Patients who present with a) known hypersensitivity to ropivacaine or to any local anesthetic agent of the amide type,
* Existing use of narcotics,
* Pregnant women,
* Individuals under the age of 18
* Procedures involving any other forms of anesthesia other than general anesthesia with a continuous popliteal nerve block.

Primary outcomes:
measure: Postoperative Pain
timeFrame: 7 days
measure: Postoperative Opioid Usage
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Rothman Orthopaedic Institute
state: Pennsylvania
Study officials:
References:
Clinical trial NCT03136822: DERMALIX Efficacy on Diabetic Foot Ulcers
Official title: Clinical Evaluation of the Wound Dressing Impregnated With Microparticules (DERMALIX) on Diabetic Foot Ulcers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetic Foot
Diabetic Foot Ulcer
Keywords: Diabetic Foot
Lead sponsor: Dermis Pharma
Sponsor class: INDUSTRY
First posted: 2017-05-02
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Open label, controlled, randomised, parallel arm study
Primary purpose: TREATMENT

Brief summary: (DERMALIX) (Patent number: PCT/TR2014/000251) is a bioactive wound dressing that was developed by Ege University School of Pharmacy Department of Pharmaceutical Technology. This dressing has been categorised as Class III medical device. This clinical study will be conducted in patients with diabetic foot ulcers.


Eligibility criteria: Inclusion Criteria:

* Type 1 or 2 Patients diagnosed with diabetic foot ulcers
* Class I and II according to Wagner classification
* No infections confirmed with culture test
* No osteomyelitis and gangrene in the foot
* HbA1c values ≤ % 7.5
* Not active smoker
* No planned treatment of hyperbaric oxygen
* Patients who give consent for the study

Exclusion Criteria:

* Patients with diabetic foot ulcer of class 3,4 and 5 according to Wagner classification
* Patients who are pregnant or breast-feeding or female who are in reproductive age applying no preservative method
* Patients who have mental conditions that lead to difficulties in comprehension
* Patients who may have compliance issues
* Patients who have been included to another interventional study with drug or medical device

Primary outcomes:
measure: Recovery of the wound 100%
timeFrame: 1 month
Secondary outcomes:
measure: Recovery of the wound 80%
timeFrame: 1 month
Other outcomes:
Locations:
city: Izmir
country: Turkey
facility: Ege University School of Medicine
Study officials:
affiliation: Ege University School of Medicine
name: Sevki Cetinkalp, Prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02449122: Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Lung Carcinoma
Official title: Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Lung Carcinoma：Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Lung Cancer
Keywords: Lung Cancer
Nano drug
Lead sponsor: Fuda Cancer Hospital, Guangzhou
Sponsor class: OTHER
First posted: 2015-05-20
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficacy of nano drug interventional therapy using digital subtraction angiography（DSA） for lung cancer. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.

Detailed description: By enrolling patients with lung cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of nano drug interventional therapy using digital subtraction angiography（DSA）for lung cancer.

The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection. The nano drug's size is detected by laser diffraction particle size analyzer.

Eligibility criteria: Inclusion Criteria:

1. Age:18-80
2. Karnofsky performance status \>60
3. Diagnosis of lung cancer based on histology or the current accepted radiological measures.
4. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ
5. Will receive interventional therapy
6. Life expectancy: Greater than 3 months
7. Patients' routine blood test, liver function and kidney function have no obvious abnormalities
8. Ability to understand the study protocol and a willingness to sign a written informed consent document

Exclusion Criteria:

1. Patients with other primary tumor except lung cancer
2. History of coagulation disorders or anemia

Primary outcomes:
measure: Number of participants with Adverse events
timeFrame: 1 year
Secondary outcomes:
measure: Percentage of lesions that show no sign of recurrence 12 months after interventional therapy
timeFrame: 1 year
measure: Progress free disease (PFS)
timeFrame: 1 year
measure: Overall survival (OS)
timeFrame: 1 year
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Central laboratory in Fuda cancer hospital
state: Guangdong
Study officials:
affiliation: Fuda Cancer Hospital
name: Lizhi Niu, PhD
role: STUDY_CHAIR
References:
citation: Niu L, Chen J, Yao F, Zhou L, Zhang C, Wen W, Bi X, Hu Y, Piao X, Jiang F, Zeng J, Liu W, Li J, He L, Mu F, Zuo J, Xu K. Percutaneous cryoablation for stage IV lung cancer: a retrospective analysis. Cryobiology. 2013 Oct;67(2):151-5. doi: 10.1016/j.cryobiol.2013.06.005. Epub 2013 Jun 24.
Clinical trial NCT04555122: COVID-19 Ad Intervention
Official title: COVID-19 Ad Intervention for Social Distancing
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Social Distance
Lead sponsor: University of California, Irvine
Sponsor class: OTHER
Collaborators: name: City University of Hong Kong
name: University of California, Los Angeles
First posted: 2020-09-18
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This study will provide advertisements to (de-identified) participants and track (de-identified) movement patterns to learn whether the ads increase adherence to stay-at-home orders.


Eligibility criteria: Inclusion Criteria:

* 18 years of age or older (as identified by company running advertisements); recent visit to a non-essential location; agreed to terms and conditions of websites allowing advertisements

Exclusion Criteria:

-

Primary outcomes:
measure: Mobility
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Irvine
country: United States
facility: UC Irvine
state: California
Study officials:
References:
Clinical trial NCT01505322: Persistent Pain to Impair Daily Activities Following Thoracic Surgery
Official title: Persistent Pain to Impair Daily Activities Following Thoracic Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pain
Keywords: daily activities
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2012-01-06
Enrollment: 396
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients having thoracic surgery for lung cancer

Brief summary: Can pain impairment of daily activities be shown to be procedure specific, and thus used as an alternative to pain scoring.


Eligibility criteria: Inclusion Criteria:

* Age \< 18 years old
* Elective lung cancer surgery (VATS)

Exclusion Criteria:

* Non-Danish residence

Primary outcomes:
measure: Pain impairment
timeFrame: >12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen,
country: Denmark
facility: Section for Surgical Pathophysiology 4074
Study officials:
affiliation: Section for Surgical Pathophysiology
name: Kim Wildgaard, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Section for Surgical Pathophysiology
name: Henrik Kehlet, MD
role: STUDY_DIRECTOR
References: